Zhejiang Jolly PharmaceuticalLTD Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Tao Wang
Chief executive officer
CN¥1.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7yrs |
| CEO ownership | n/a |
| Management average tenure | 5.5yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Does Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Deserve A Spot On Your Watchlist?
Nov 28
Investors Still Aren't Entirely Convinced By Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Earnings Despite 32% Price Jump
Oct 17These 4 Measures Indicate That Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Is Using Debt Safely
Oct 06It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)
Aug 30We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease
Jul 29Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%
May 13A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)
May 08There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings
Mar 01CEO
Tao Wang (56 yo)
7yrs
Tenure
CN¥1,092,500
Compensation
Mr. Tao Wang serves as General Manager at Zhejiang Jolly Pharmaceutical Co., Ltd. since January 16, 2018 and has been its Non-Independent Director since May 10, 2024 and also served as its Senior Manager a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Non-Independent Director | 7yrs | CN¥1.09m | no data | |
| Deputy GM & Non-Independent Director | 4yrs | CN¥743.10k | no data | |
| Executive Deputy GM | 2.8yrs | CN¥807.50k | 0.095% CN¥ 9.8m | |
| Deputy General Manager | 17yrs | CN¥606.70k | 0.15% CN¥ 15.4m | |
| Deputy General Manager | 7yrs | CN¥711.50k | no data | |
| Deputy General Manager | 2yrs | CN¥721.30k | 0.0028% CN¥ 283.3k |
5.5yrs
Average Tenure
51.5yo
Average Age
Experienced Management: 300181's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Non-Independent Director | less than a year | CN¥1.09m | no data | |
| Deputy GM & Non-Independent Director | 4yrs | CN¥743.10k | no data | |
| Executive Deputy GM | 8yrs | CN¥807.50k | 0.095% CN¥ 9.8m | |
| Chairman | 21.4yrs | CN¥1.03m | 18.92% CN¥ 1.9b | |
| Non-Independent Director | 4yrs | CN¥20.00k | no data | |
| Non-Independent Director | 17yrs | CN¥20.00k | 0.11% CN¥ 10.9m | |
| Non-Independent Director | 8yrs | CN¥20.00k | no data | |
| Independent Director | 4.8yrs | CN¥60.00k | no data | |
| Independent Director | 4yrs | CN¥60.00k | no data | |
| Independent Director | 4yrs | CN¥60.00k | no data | |
| Chairman of the Supervisory Board | 6.9yrs | no data | no data | |
| Independent Director | less than a year | no data | no data |
4.4yrs
Average Tenure
52yo
Average Age
Experienced Board: 300181's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 12:08 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Jolly Pharmaceutical Co.,LTD is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Mingrui Wang | Everbright Securities Co. Ltd. |
| Suqing Huang | Everbright Securities Co. Ltd. |